Comparative Pharmacology
Head-to-head clinical analysis: GALLIUM GA 68 GOZETOTIDE versus MPI DMSA KIDNEY REAGENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GALLIUM GA 68 GOZETOTIDE versus MPI DMSA KIDNEY REAGENT.
GALLIUM GA 68 GOZETOTIDE vs MPI DMSA KIDNEY REAGENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gallium Ga 68 gozetotide is a radioactive diagnostic agent that binds to prostate-specific membrane antigen (PSMA), a transmembrane protein overexpressed on prostate cancer cells. After binding, the gallium-68 isotope emits positrons for PET imaging.
DMSA (dimercaptosuccinic acid) labeled with technetium-99m binds to renal cortex, particularly proximal tubular cells, allowing scintigraphic imaging of functional renal parenchyma. Uptake correlates with renal blood flow and tubular function.
148-222 MBq (4-6 mCi) intravenously as a single dose for PET imaging.
Adults: 74-185 MBq (2-5 mCi) intravenously, single dose for renal imaging.
None Documented
None Documented
Terminal elimination half-life: 1.5 hours (range 1.2–1.8 hours) based on decay of Gallium-68 and renal clearance. Clinically, this allows imaging up to 2–3 hours post-injection.
Initial whole-body half-life of dimer captosuccinic acid (DMSA) is 1.1 hours; terminal elimination half-life for cortical retention is 56 days, reflecting prolonged renal tubular uptake.
Renal excretion: 100% of administered dose eliminated unchanged in urine within 24 hours. No biliary or fecal elimination significant.
Renal: ~50% excreted unchanged in urine within 24 hours; remaining fraction retained in renal tubular cells with gradual release over weeks.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical